Searched for
CIPLA SHARES
Cipla subsidiary clears USFDA inspection with zero observationsCipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' m...- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Nifty 50 companies likely to log strong double-digit growth in Q2Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by ...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Stocks in news: Groww, Tata Motors PV, Cipla, Varun Beverages and Axis BankThe Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Ant...
- Cipla Q1 Results: Cons profit drops 39% YoY to Rs 789 crore; revenue rises marginallyCipla Q1 Results: Pharma major Cipla reported a 39% year-on-year decline in Q1FY27 consolidated net profit to Rs 789 crore, mainly due to a...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...
- Cipla shares in focus after deal to acquire Inzpera Healthsciences for Rs 111 croreCipla shares: Cipla has agreed to acquire a 100% stake in Inzpera Healthsciences, making it a wholly owned subsidiary, as part of its strat...
- Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...
- Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates re...
- Cipla shares in focus after Goa facility receives form 483 with one observation from USFDACipla share price has risen by 10% over the past 12 months and 64% over the last three years. The company's current market capitalization i...
- Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to ‘buy’Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a targe...
- Cipla shares in focus as promoters Samina and Rumana Hamied offload 1.72% stake for Rs 2,111 croreCipla shares are in focus today after Samina Hamied and Rumana Hamied, promoters of the pharmaceutical company, exited by selling their 1.7...
- Cipla shares in focus on Rs 2,000 crore likely block dealCipla's shares are likely to attract attention on Monday as the company's promoters may sell up to a 1.72% stake through block deals. The o...
- Cipla stock in focus after Q2 PAT beats estimates. Should you buy, sell or hold?Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 2024. Revenue ro...
- Cipla skids 4% on Jan-Mar earnings missThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- Dispute settlement gives this stock an edge over peers in pharma packKunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settle...
- Analysts give a thumbs up to Cipla’s Q2 report card, see 30% upside in the stockJefferies was the most optimistic as it maintained its buy rating on the stock, and raised the target price to Rs 1,024 from Rs 914 earlier.
Load More
